Efficacy, Pharmacokinetics, and Safety of BI 695500 in Patients With Rheumatoid Arthritis



Status:Terminated
Conditions:Arthritis, Rheumatoid Arthritis
Therapuetic Areas:Rheumatology
Healthy:No
Age Range:18 - 80
Updated:2/1/2018
Start Date:September 5, 2012
End Date:October 12, 2016

Use our guide to learn which trials are right for you!

Efficacy, Pharmacokinetics, and Safety of BI 695500 Versus Rituximab in Patients With Moderately to Severely Active Rheumatoid Arthritis: a Randomized, Double-blind, Parallel Arm, Multiple Dose, Active Comparator Trial.

The primary objectives of this trial are (1) To show PK (Pharmacokinetic) similarity of BI
695500 to rituximab. (2)To establish statistical equivalence of efficacy of BI 695500 and
rituximab, in patients with moderately to severely active RA (Rheumatoid Arthritis), based on
the change in Disease Activity Score 28 (DAS28) score measured at 24 weeks compared to
Baseline and the American College of Rheumatology 20% (ACR20) response rate at Week 24.


Inclusion criteria:

1. Must give written informed consent and be willing to follow the protocol.

2. Male or female participants, between 18 and 80 years of age, who have a diagnosis of
moderately to severely active RA for at least 6 months as defined by at least six
swollen joints (66 joint count) and at least eight tender joints (68 joint count) at
Screening and Baseline (Day 1), and either an erythrocyte sedimentation rate (ESR) of
> 28 mm/hour OR a C-reactive protein (CRP) level > 1.0 mg/dL (normal: < 0.4 mg/dL) at
Screening. Patients must have had an inadequate response or intolerance to
conventional DMARD therapy including at least one tumor necrosis factor (TNF)
inhibitor.

3. Positive for Radio Frequency and/or anti-CCP (Anti-cyclic citrullinated peptide)
antibodies.

4. Current treatment for RA on an outpatient basis:

1. Must be currently receiving and tolerating oral or parenteral MTX therapy at a
dose of 15-25 mg per week (dose may be as low as 10 mg per week if the patient is
unable to tolerate a higher dose) for at least 12 weeks immediately prior to Day
1. The dose should be stable for at least 4 weeks prior to Day 1 until Week 24.
After Week 24 the administration route can be changed at the investigator's
discretion.

2. Patients must be willing to receive oral folic acid (at least 5 mg/week or as per
local practice) or equivalent during the entire study (mandatory co-medication
for MTX treatment).

3. Biologic agents and DMARDs (other than MTX) must be withdrawn at least 2 weeks
prior to Day 1, except azathioprine and etanercept which must be withdrawn at
least 4 weeks prior to Day 1; abatacept, adalimumab, anakinra, certolizumab,
infliximab, and golimumab at least 8 weeks prior to Day 1; tocilizumab at least
10 weeks prior to Day 1.

4. Leflunomide must be withdrawn at least 8 weeks prior to Day 1 or a minimum of 2
weeks prior to Day 1 if after 11 days of standard cholestyramine washout.

5. If receiving current treatment with oral corticosteroids (other than
intra-articular or parenteral), the dose must not exceed 10 mg/day prednisolone
or equivalent. During the 4 weeks prior to Baseline (Day 1) the dose must remain
stable.

6. Intra-articular and parenteral corticosteroids are not permitted within 6 weeks
prior to Baseline Day 1 or throughout the trial, with the exception of IV
administration of 100 mg methylprednisolone 30 to 60 minutes prior to each
infusion as this is part of the trial procedures.

7. Any concomitant non-steroidal anti-inflammatory drugs (NSAIDs) must be stable for
at least 2 weeks prior to Day 1.

8. Patients may be taking oral hydroxychloroquine provided that the dose is not
greater than 400 mg/day or chloroquine provided that the dose is not greater than
250 mg/day. These doses must have been stable for a minimum of 12 weeks prior to
Day 1. The hydroxychloroquine or chloroquine treatment will need to be continued
at a stable dose with the same formulation until the end of the trial.

5. For participants of reproductive potential (males and females), use of a reliable
means of contraception (e.g., hormonal contraceptive, patch, intrauterine device,
physical barrier) has to be used throughout trial participation. Females of
child-bearing potential must also agree to use an acceptable method of contraception
for 12 months following completion or discontinuation from the trial.

Exclusion criteria:

1. ACR functional Class IV or wheelchair/bed bound.

2. Primary or secondary immunodeficiency (history of, or currently active), including
known history of human immunodeficiency virus infection.

3. History of positive purified protein derivative test (positive tuberculosis [TB] test)
without treatment for TB infection or chemoprophylaxis for TB exposure.

4. Positive HIV or TB at screening.

5. Known coronary artery disease or significant cardiac arrhythmias or severe congestive
heart failure (New York Heart Association classes III or IV), or interstitial lung
disease observed on chest X-ray.

6. History of IgE-mediated (immunoglobulin E) or non-IgE-mediated hypersensitivity or
known anaphylaxis to mouse proteins or a history of hypersensitivity to antibody
therapy.

7. History of cancer including solid tumors, hematologic malignancies, and carcinoma in
situ (except participants with previous resected and cured basal or squamous cell
carcinoma, treated cervical dysplasia, or treated in situ Grade I cervical cancer
within 5 years prior to the Screening Visit).

8. History of pancreatitis or current peptic ulcer disease.

9. Receipt of a live/attenuated vaccine within 12 weeks prior to the Screening Visit.

10. Any condition or treatment (including biologic therapies) that, in the opinion of the
investigator, may place the patient at unacceptable risk during the trial.

11. Pregnancy or breast feeding.

12. History of, or current, inflammatory joint disease other than RA (e.g., gout, reactive
arthritis, psoriatic arthritis, seronegative spondyloarthropathy, Lyme disease) or
other systemic autoimmune disorder (e.g., systemic lupus erythematosus, inflammatory
bowel disease, pulmonary fibrosis, or Feltys syndrome, scleroderma, inflammatory
myopathy, mixed connective tissue disease, or any overlap syndrome).

13. Diagnosis of juvenile idiopathic arthritis, also known as juvenile RA, and/or RA
before age 16.

14. Any surgical procedure, including bone/joint surgery/synovectomy (including joint
fusion or replacement) within 12 weeks prior to the Screening Visit or planned within
24 weeks of the Screening Visit.

15. Lack of peripheral venous access.

16. Evidence of significant uncontrolled concomitant disease such as, but not limited to,
nervous system, renal, hepatic, endocrine, or gastrointestinal disorders which, in the
investigator's opinion, would preclude patient participation.

17. Known concurrent viral hepatitis or known positivity to HBe-ag, HBV DNA, HBV DNA
polymerase, HCVRNA, anti HCV antibodies.

18. Known active infection of any kind (excluding fungal infections of nail beds), or any
major episode of infection requiring hospitalization or treatment with IV
anti-infectives within 4 weeks of the Screening Visit or completion of oral
anti-infectives within 2 weeks of the Screening Visit.

19. History of deep space/tissue infection (e.g., fasciitis, abscess, osteomyelitis)
within 52 weeks of the Screening Visit.

20. History of serious infection or opportunistic infection in the last 2 years.

21. Any neurological (congenital or acquired), vascular or systemic disorder that might
affect any of the efficacy assessments, in particular, joint pain and swelling (e.g.,
Parkinson's disease, cerebral palsy, diabetic neuropathy).

22. Currently active alcohol or drug abuse or history of alcohol or drug abuse (as
determined by the investigator) within 52 weeks of the Screening Visit.

23. Treatment with IV Gamma Globulin or the Prosorba® Column within 6 months of the
Screening Visit.

24. Treatment with IV or intramuscular corticosteroids.

25. Previous treatment with a B cell modulating or cell depleting therapy.

26. Intolerance or contraindications to IV glucocorticoids.

27. AST (aspartate aminotransferase) or ALT (alanine aminotransferase)> 3 times ULN (Upper
Limit of Normal)

28. Hemoglobin < 8.0 g/dL.

29. Levels of IgG < 5.0 g/L.

30. Absolute neutrophil count < 1500/µL.

31. Platelet count < 75000/µL.

32. Participation in any previous clinical trial within 12 weeks of Screening.
We found this trial at
54
sites
2017 Canyon Road, Suite 41
Birmingham, Alabama 35216
(205) 757-8208
Site Overview Achieve has two clinical research sites in Birmingham, AL. Our Birmingham sites are conveniently located...
?
mi
from
Birmingham, AL
Click here to add this to my saved trials
860 Peachwood Drive
DeLand, Florida 32720
(386) 740-0770
Site Overview Avail Clinical Research is a renowned and experienced clinical research site conducting Phase...
?
mi
from
DeLand, FL
Click here to add this to my saved trials
Albuquerque, New Mexico 87102
?
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Beckley, West Virginia 25801
?
mi
from
Beckley, WV
Click here to add this to my saved trials
Birmingham, Alabama 35205
?
mi
from
Birmingham, AL
Click here to add this to my saved trials
Bridgeport, Connecticut 06606
?
mi
from
Bridgeport, CT
Click here to add this to my saved trials
?
mi
from
Brooklyn, NY
Click here to add this to my saved trials
Buenos Aires, 1878
?
mi
from
Buenos Aires,
Click here to add this to my saved trials
6300 Stonewood Drive
Carrollton, Texas 75007
?
mi
from
Carrollton, TX
Click here to add this to my saved trials
10502 Park Road
Charlotte, North Carolina 28210
?
mi
from
Charlotte, NC
Click here to add this to my saved trials
Chicago, Illinois 60616
?
mi
from
Chicago, IL
Click here to add this to my saved trials
Clarksburg, West Virginia 26301
?
mi
from
Clarksburg, WV
Click here to add this to my saved trials
Clifton, New Jersey 07012
?
mi
from
Clifton, NJ
Click here to add this to my saved trials
Coeur d'Alene, Idaho 83814
?
mi
from
Coeur d'Alene, ID
Click here to add this to my saved trials
Columbia, Maryland 21045
?
mi
from
Columbia, MD
Click here to add this to my saved trials
Corpus Christi, Texas 78404
?
mi
from
Corpus Christi, TX
Click here to add this to my saved trials
Covina, California 91723
?
mi
from
Covina, CA
Click here to add this to my saved trials
Cumberland, Maryland 21502
?
mi
from
Cumberland, MD
Click here to add this to my saved trials
Dayton, Ohio 45417
?
mi
from
Dayton, OH
Click here to add this to my saved trials
Duncansville, Pennsylvania 16635
?
mi
from
Duncansville, PA
Click here to add this to my saved trials
El Cajon, California 92020
?
mi
from
El Cajon, CA
Click here to add this to my saved trials
?
mi
from
Glendale, AZ
Click here to add this to my saved trials
Grand Rapids, Michigan 49546
?
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
Greensboro, North Carolina 27408
?
mi
from
Greensboro, NC
Click here to add this to my saved trials
Houston, Texas 77034
?
mi
from
Houston, TX
Click here to add this to my saved trials
Idaho Falls, Idaho 83404
?
mi
from
Idaho Falls, ID
Click here to add this to my saved trials
Lakewood, California 90712
?
mi
from
Lakewood, CA
Click here to add this to my saved trials
Lakewood, California 90712
?
mi
from
Lakewood, CA
Click here to add this to my saved trials
Little Rock, Arkansas 72205
?
mi
from
Little Rock, AR
Click here to add this to my saved trials
Long Beach, California 90808
?
mi
from
Long Beach, CA
Click here to add this to my saved trials
McKinney, Texas 75069
?
mi
from
McKinney, TX
Click here to add this to my saved trials
Memphis, Tennessee 38119
?
mi
from
Memphis, TN
Click here to add this to my saved trials
?
mi
from
Mesa, AZ
Click here to add this to my saved trials
Miami, Florida 33175
?
mi
from
Miami, FL
Click here to add this to my saved trials
Nashville, Tennessee 37203
?
mi
from
Nashville, TN
Click here to add this to my saved trials
3555 NW 58th St # 800
Oklahoma City, Oklahoma 73112
(405) 447-8839
Lynn Health Science Institute Our mission is to provide clinical trials research and health services...
?
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Omaha, Nebraska 68114
?
mi
from
Omaha, NE
Click here to add this to my saved trials
Orlando, Florida 32804
?
mi
from
Orlando, FL
Click here to add this to my saved trials
Overland Park, Kansas 66210
?
mi
from
Overland Park, KS
Click here to add this to my saved trials
1601 North Palm Avenue
Pembroke Pines, Florida 33026
?
mi
from
Pembroke Pines, FL
Click here to add this to my saved trials
?
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Saint Louis, Missouri 63141
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
San Diego, California 92108
?
mi
from
San Diego, CA
Click here to add this to my saved trials
Santa Maria, California 93454
?
mi
from
Santa Maria, CA
Click here to add this to my saved trials
Seattle, Washington 98133
?
mi
from
Seattle, WA
Click here to add this to my saved trials
Tacoma, Washington 98405
?
mi
from
Tacoma, WA
Click here to add this to my saved trials
?
mi
from
Tampa, FL
Click here to add this to my saved trials
Thousand Oaks, California 91360
?
mi
from
Thousand Oaks, CA
Click here to add this to my saved trials
Toms River, New Jersey 08755
?
mi
from
Toms River, NJ
Click here to add this to my saved trials
?
mi
from
Upland, CA
Click here to add this to my saved trials
411 Commercial Court
Venice, Florida 34292
?
mi
from
Venice, FL
Click here to add this to my saved trials
Webster, Texas 77598
?
mi
from
Webster, TX
Click here to add this to my saved trials
?
mi
from
Wheaton, MD
Click here to add this to my saved trials
Worcester, Massachusetts 01610
?
mi
from
Worcester, MA
Click here to add this to my saved trials